ANI-7

ANI-7 is an activator of aryl hydrocarbon receptor (AhR) pathway. ANI-7 inhibits the growth of multiple cancer cells, and potently and selectively inhibits the growth of MCF-7 breast cancer cells with a GI50 of 0.56 μM. ANI-7 induces CYP1-metabolizing mono-oxygenases by activating AhR pathway, and also induces DNA damage, checkpoint Kinase 2 (Chk2) activation, S-phase cell cycle arrest, and cell death in sensitive breast cancer cell lines[1][2][3].

Product Specifications

CAS Number

[931417-26-4]

Product Name Alternative

Prodigiosine (hydrochloride)

UNSPSC

12352005

Target

Aryl Hydrocarbon Receptor; Checkpoint Kinase (Chk)

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Immunology/Inflammation

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ani-7.html

Concentration

10mM

Purity

99.01

Solubility

DMSO : 20.83 mg/mL (ultrasonic)

Smiles

ClC1=CC(/C(C#N)=C/C2=CC=CN2)=CC=C1Cl

Molecular Formula

C13H8Cl2N2

Molecular Weight

263.12

References & Citations

[1]ilbert J, et al. (Z) -2- (3,4-Dichlorophenyl) -3- (1H-Pyrrol-2-yl) Acrylonitrile Exhibits Selective Antitumor Activity in Breast Cancer Cell Lines via the Aryl Hydrocarbon Receptor Pathway. Mol Pharmacol. 2018 Feb;93 (2) :168-177.|[2]Baker JR, et al. Dichlorophenylacrylonitriles as AhR Ligands That Display Selective Breast Cancer Cytotoxicity in vitro. ChemMedChem. 2018 Jul 18;13 (14) :1447-1458.|[3]Mark Tarleton, et al. Library synthesis and cytotoxicity of a family of 2-phenylacrylonitriles and discovery of an estrogen dependent breast cancer lead compound. Medicinal Chemistry Communication. January 20112. (1) :31-37.